Akros SCHK HK-Global Genomics Index

Natera is expected to announce its Q2 2026 earnings results on or around August 6, 2026, scheduled. High importance is estimated due to typical high volatility (>10%) following earnings reports.

Illumina is scheduled to release its financial results for the second quarter of 2026 after the market closes on July 30, 2026, with a conference call to follow; a price impact of ≥5% is estimated based on historical volatility scheduled

Announced that its Signatera personalized molecular residual disease (MRD) test received certification as a Class C device under the European Union's In Vitro Diagnostic Regulation (IVDR) on July 9, 2026. Medium importance is estimated based on market expansion potential (>5%).

Illumina announced the appointment of Mike Sullivan as Chief Commercial Officer (effective July 20, 2026) and Julie Coletti as Chief Legal Officer (effective August 3, 2026) to strengthen its executive team; a price impact of ≥1% is estimated based on market norms scheduled

Evercore ISI lowered its price target on Caris Life Sciences to $25 from $30, while maintaining an 'Outperform' rating on July 6, 2026.